Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in inoperable CTEPH (open-label extension of MERIT-1)
CTR20140739Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of macitentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Started Jan 2016; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on CTR20140739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140739.